Evidence map›Paper›PMID 40357896›Full record

ArticlePhotochemistry and photobiology

Image-based treatment planning for TLD1433 mediated intraoperative photodynamic therapy with an optical surface applicator-A translational rodent study.

Sarah Chamberlain, Ge Shi, Sandra Sexton, Alisher Talgatov, Saraswati Pokharel, David Bellnier, Alan Hutson, Colin G Cameron, Girgis Obaid, Sherri A McFarland and 1 more

Abstract read
In one paragraph

Article in Photochemistry and photobiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarah ChamberlainDepartment of Cell Stress Biology, Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Ge ShiDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, Texas, USA.
Sandra SextonComparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Alisher TalgatovDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, Texas, USA.
Saraswati PokharelDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
David BellnierDepartment of Cell Stress Biology, Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Alan HutsonDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Colin G CameronDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, Texas, USA.
Girgis ObaidDepartment of Bioengineering, The University of Texas at Dallas, Richardson, Texas, USA.ORCID 0000-0002-9452-4467
Sherri A McFarlandDepartment of Chemistry and Biochemistry, The University of Texas at Arlington, Arlington, Texas, USA.ORCID 0000-0002-8028-5055
Gal ShafirsteinDepartment of Cell Stress Biology, Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Molecular Imaging Guidance for Potentiating Chemoimmunotherapy in Pancreatic Cancer using Photodynamic PrimingR01EB034360 · NIBIB · UNIVERSITY OF TEXAS DALLAS · PI Girgis Obaid · 2024 to 2026
$1.6M
Optical Surface Applicator Light Dosimetry for Ruthenium-based Photosensitizer Mediated Intraoperative Photodynamic TherapyR21CA256537 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI SHAFIRSTEIN, GAL · 2021 to 2022
$422k
Cancer Prevention and Research Institute of Texas RP240498NCI NIH HHS P30 CA016056NCI NIH HHS P30CA016056NCI NIH HHS R21 CA256537NIBIB NIH HHS R01 EB034360NIH HHS R01EB034360NIH HHS R21CA256537
6 · The paper itself

Abstract

Several clinical studies suggest that following surgical resection, intraoperative photodynamic therapy (intraoperative PDT) has the potential to reduce local recurrence and improve overall survival in patients diagnosed with pleural dissemination of lung cancer. The response to intraoperative PDT depends on the light dose rate (irradiance) and dose (fluence) as well as the intratumoral concentration of the photosensitizer and oxygenation. We seek to advance intraoperative PDT by improving the control of irradiance and fluence with image-based treatment planning for an optical surface applicator (OSA) with a novel photosensitizer (TLD1433) that has shown safety in recent clinical trials. To that end, we tested the accuracy of Monte Carlo-based simulations of light delivery from the OSA in vitro and in vivo. We assess the safety and biodistribution after the instillation of TLD1433 in the peritoneal cavity of mice and rats, and define the relationship between the intratumoral irradiance and fluence, and the volume of tumor ablation in the peritoneal cavity of rats. The Monte Carlo simulations agreed with light dosimetry measurements at a 5-mm prescription depth in vitro. An instillation of TLD1433 in the peritoneal cavity of mice is safe and leads to drug accumulation in the tumor and adjacent organs in the peritoneal cavity of rats. A TLD1433-mediated intraoperative PDT procedure using an instilled dose of 14 mg/kg and 532-nm laser light induces tumor cell degradation in the peritoneal cavity of rats. Our results suggest that the Monte Carlo simulation can be used as an image-based treatment plan for administering a controlled PDT procedure with OSA and TLD1433.

Indexed as

PhotochemotherapyPhotosensitizing AgentsAnimalsIntraoperative CareIntraoperative PeriodMiceMonte Carlo MethodRatsTissue DistributionPhotosensitizing Agentsintraoperative photodynamic therapyoptical surface applicatorTLD1433treatment planning

Identifiers

PMID40357896
PMCPMC12353992

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.